PDCD1 and metastatic melanoma: Consistent with these findings, the phase 3 clinical trial RELATIVITY-047 in patients with treatment-naive metastatic melanoma has demonstrated a significantly longer progression-free survival with the combination of anti-PD-1 and anti-LAG-3 monoclonal antibodies (mAbs) than with anti-PD-1 monotherapy35.